Skip to main content

Advertisement

SpringerLink
Log in

Mizoribine therapy in a patient with lupus nephritis: the association between mizoribine concentration and peritoneal dialysis

  • Case Report
  • Published:
Modern Rheumatology

Abstract

We describe a 20-year-old female with systemic lupus erythematosus (SLE) who developed renal failure during continuous ambulatory peritoneal dialysis (CAPD). The patient was treated with mizoribine (MZR). MZR peak concentration was 1.8 μg/ml and was sufficient for clinical efficacy as measured by serological data. Treatment with MZR was safe and useful even while undergoing CAPD. Achieving optimal MZR blood concentration was important for treatment of SLE, even though the patient was in end-stage renal failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K, Matsuda T. Studies on Bredinin. I. Isolation, characterization and biological properties. J Antibiot (Tokyo). 1974;27:775–84.

    CAS  Google Scholar 

  2. Ishikawa H. Mizolobine and mycophenolate Mofetil. Curr Med Chem. 1999;6:575–97.

    CAS  PubMed  Google Scholar 

  3. Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent development in molecular action and chemical application. Transplant Proc. 1998;1:89–90.

    Google Scholar 

  4. Suthanthiran M, Morris RE, Strom TB. Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis. 1996;28:159–72.

    Article  CAS  PubMed  Google Scholar 

  5. Hughes SE, Gruber SA. New immunosuppressive drugs in organ transplantation. J Clin Pharmacol. 1996;36:1081–92.

    CAS  PubMed  Google Scholar 

  6. Kokado Y, Ishibashi I, Jiang H. Low dose cyclosporine, mizoribine and prednisolone in renal transplantation: a new triple therapy. Clin Transplant. 1990;4:191–7.

    Google Scholar 

  7. Inoue T, Kusaba R, Takahashi I, Sugumoto H, Kuzuhara K, Yamada Y, et al. Clinical trial of Bredinine in renal transplantation. Transplant Proc. 1981;13:315–8.

    Google Scholar 

  8. Shiokawa Y, Akizuki R, Yokohari R, Hashimoto H, Kashiwazaki S, Kondo H, et al. Clinical evaluation of mizoribine on rheumatoid arthritis: a double-blind comparative study using lobenzariddisodium as a standard drug (in Japanese). Igakunoayumi. 1991;156:811–31.

    Google Scholar 

  9. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequency relapsing nephritic syndrome. Kidney Int. 2000;58:317–24.

    Article  CAS  PubMed  Google Scholar 

  10. Kaneko K, Nagaoka R, Ohtomo Y, Yamashiro Y. Mizoribine for childhood IgA nephropathy. Nephron. 1999;83:376–7.

    Article  CAS  PubMed  Google Scholar 

  11. Aihara Y, Miyamae T, Ito S, Kobayashi S, Imagawa T, Mori M, et al. Mizoribine as an effective combined maintenance therapy with prednisolone in childhood-onset systemic lupus erythematosus. Pediatr Int. 1999;19:2–11.

    Google Scholar 

  12. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Wada S. Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis. Clin Nephrol. 2003;60:390–4.

    CAS  PubMed  Google Scholar 

  13. Fukunishi T, Takahashi S, Hashinaka Y, Oota K, Nagano S, Takada K, et al. Bredinine concentration in blood and immunosuppressive effect (in Japanese). Ishyoku Jpn J Transplant. 1982;17(Suppl):750–2.

    Google Scholar 

  14. Sonda K, Takahashi K, Tanabe K, Funchinose S, Hayasaka Y, Kawaguchi H, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc. 1996;28:3643–8.

    CAS  PubMed  Google Scholar 

  15. Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, et al. Mizoribine therapy for patients with lupus nephritis: the association for peak mizoribine concentration and clinical efficacy. Mod Rheumatol. 2007;17:206–12.

    Article  CAS  PubMed  Google Scholar 

  16. Shetty H, Gokal R. Peritoneal dialysis as the first-choice treatment. Ronco C, Dell’Aquila R, Rodighiero MP, editors. Peritoneal dialysis today. Contrib Nephrol. vol 140. Basel: Karger; 2003. p. 218–225.

  17. Japanese Society of Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec. 31, 2008. 2009:1–22 (in Japanese).

  18. Tanaka H, Oki E, Tsuruga K, Sato N, Matsukura H, Matsunaga A, et al. Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku pediatric study group. Nephron Clin Pract. 2008;110:c73–9.

    Article  CAS  PubMed  Google Scholar 

  19. Kasama T, Wakabayashi K, Odai T, Isozaki T, Matsunawa M, Yajima N, et al. Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate. Mod Rheumatol. 2009;19(4):395–400.

    Article  CAS  PubMed  Google Scholar 

  20. Doi T, Masaki T, Shiraki N, Kawai T, Yorioka N. Oral mizoribine pulse therapy for steroid-dependent focal segmental glomerulosclerosis. Clin Nephrol. 2008;69:433–5.

    CAS  PubMed  Google Scholar 

  21. Ikezumi Y, Suzuki T, Karasawa T, Kawachi H, Nikolic-Paterson DJ, Uchiyama M. Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy. Pediatr Nephrol. 2008;23:645–50.

    Article  PubMed  Google Scholar 

  22. Tsubouchi Y, Fukuda W, Kawahito K, Kohno M, Wada M, Ishino H, et al. A case of lupus nephritis improved after appropriately adjusting the dosage of mizoribine. Mod Rheumatol. 2008;18:91–5.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Asahi-Kasei Pharm, Tokyo, for the measurements and analysis of the blood levels of MZR.

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Cyuuou-ku, Niigata, 951-8510, Japan

    Takeshi Kuroda, Daisuke Kobayashi, Hiroe Sato, Akihisa Oyanagi, Yoko Wada, Syuichi Murakami & Ichiei Narita

  2. Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, 2-746 Asahimachi-Dori, Niigata, 951-8518, Japan

    Masaaki Nakano

Authors
  1. Takeshi Kuroda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daisuke Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroe Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akihisa Oyanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoko Wada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Syuichi Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masaaki Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ichiei Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Kuroda.

About this article

Cite this article

Kuroda, T., Kobayashi, D., Sato, H. et al. Mizoribine therapy in a patient with lupus nephritis: the association between mizoribine concentration and peritoneal dialysis. Mod Rheumatol 20, 296–300 (2010). https://doi.org/10.1007/s10165-009-0267-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-009-0267-9

Keywords

Search

Navigation